Page 159 - Binder2

In a tolerance-first biotech:

• IP strategy protects not just molecules, but delivery
platforms and adjuvant synergies
• Regulatory engagement includes proactive
conversations about immune markers, not just
efficacy endpoints
• Reimbursement planning is tied to value-based
metrics like drug survival, not volume
• Partnering strategy favors like-minded
collaborators—platform companies, biosimilar
disruptors, and value-based care systems

Durability becomes a market edge.
Immune compatibility becomes a talking point in investor
decks.
And the brand becomes synonymous with biologics that
last.

The Result: Fewer Switches, Greater Trust,
Longer Lifespans

The net result of this model isn’t just scientific. It’s
systemic.

You build biologics that:

• Last longer in patients
• Require fewer escalations
• Elicit fewer ADAs
• Inspire more confidence among prescribers
• Create a new trust contract with patients

157